QRxPharma LTD (QRx) is an Australian specialty pharmaceutical company that develops and commercializes pain therapy products.

According to the law firm press release, the Complaint alleges that QRx issued false and misleading public statements and omitted material facts concerning the commercial prospects for its experiment drug Moxduo. Specifically, the Complaint alleges that QRx failed to disclose to investors that it received a no agreement letter from the Food and Drug Administration (FDA) regarding its Moxduo trials and further misrepresented and concealed other material facts concerning its attempts to get Moxduo approved. Upon the disclosure of an FDA memorandum which denied QRx's application to get Moxduo approved, the price of QRx ADRs plummeted over
83% on April 23, 2014.

On September 14, 2015, the Court appointed lead Plaintiffs and approved lead Counsel. Lead Plaintiffs filed an amended Complaint on November 23. A second amended Complaint was filed on January 4, 2016.

On July 6, 2016, the Court issued an Order dismissing this case with prejudice.